DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue

Diabetes, Obesity and Metabolism

Volumn 11, Issue 4, 2009, Pages 285-292

  Kos, K ^a   Baker, A R ^a   Jernas, M ^b   Harte, A L ^a   Clapham, J C ^c   O'Hare, J P ^a   Carlsson, L ^b   Kumar, S ^a   Mcternan, Philip G ^a,d  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Adipose tissue; DPP IV; DPP IV inhibitors; Human metabolism; Metabolic syndrome; NPY; Obesity

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCEROL; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; RECOMBINANT NEUROPEPTIDE Y; UNCLASSIFIED DRUG; DPP4 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOCYTE; ADIPOSE TISSUE; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID METABOLISM; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; TISSUE DISTRIBUTION; WEIGHT REDUCTION; CELL CULTURE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OBESITY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADIPOCYTES; ADULT; CELLS, CULTURED; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLYCEROL; HUMANS; LIPOLYSIS; MIDDLE AGED; NEUROPEPTIDE Y; OBESITY; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT, ABDOMINAL;

EID: 61549105354     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00909.x     Document Type: Article

References (27)

1. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36: 867-876.
2. Burkey BF, Li X, Bolognese L, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005; 315: 688-695.
3. Langley AK, Suffoletta TJ, Jennings HR. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 2007; 27: 1163-1180.
4. Heymann E, Mentlein R. Has dipeptidyl peptidase IV an effect on blood pressure and coagulation? Klin Wochenschr 1984; 62: 2-10.
5. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
6. Chronwall BM, Zukowska Z. Neuropeptide Y, ubiquitous and elusive. Peptides 2004; 25: 359-363.
7. Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol 2005; 184: 291-318.
8. Billington CJ, Briggs JE, Grace M, Levine AS. Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 1991; 260: 321-327.
9. Serradeil-Le Gal C, Lafontan M, Raufaste D, et al. Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes. FEBS Lett 2000; 475: 150-156
10. Valet P, Berlan M, Beauville M, Crampes F, Montastruc JL, Lafontan M. Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a Pertussis toxin-sensitive G protein. J Clin Invest 1990; 85: 291-295.
11. Bradley RL, Mansfield JP, Maratos-Flier E. Neuropeptides, including neuropeptide y and melanocortins, mediate lipolysis in murine adipocytes. Obes Res 2005; 13: 653-661.
12. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: A novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83: 187-195.
13. Harte A, McTernan P, Chetty R, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 2005; 111: 1954-1961.
14. Kos K, Harte AL, James S, et al. Secretion of Neuropeptide Y (NPY) in human adipose tissue and its role in maintenance of adiposity. Am J Physiol Endocrinol Metab 2007; 293: 1335-1340.
15. Jernås M, Palming J, Sjöholm K, et al. Separation of human adipocytes by size: Hypertrophic fat cells display distinct gene expression. FASEB J 2006; 20: 1540-1542.
16. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001; 29: 365-371.
17. Sudre B, Broqua P, White RB, et al. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002; 51: 1461-1469.
18. Castan I, Valet P, Quideau N, et al. Antilipolytic effects of alpha 2-adrenergic agonists, neuropeptide Y, adenosine, and PGE1 in mammal adipocytes. Am J Physiol 1994; 266: 1141-1147.
19. Labelle M, Boulanger Y, Fournier A, St Pierre S, Savard R. Tissue-specific regulation of fat cell lipolysis by NPY in 6-OHDA-treated rats. Peptides 1997 18: 801-808.
20. Turtzo LC, Marx R, Lane MD. Cross-talk between sympathetic neurons and adipocytes in coculture. Proc Natl Acad Sci USA 2001; 98: 12385-12390.
21. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132-138.
22. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447
23. Chu XY, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007; 321: 673-683.
24. Nilsson C, Westmann, A, Blennow W, Ekman R. Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry. Peptides 1998; 19: 1137-1146.
25. Kalra PS, Dube MG, Xu B, Farmerie WG, Kalra SP. Neuropeptide Y (NPY) Y1 receptor mRNA is upregulated in association with transient hyperphagia and body weight gain: Evidence for a hypothalamic site for concurrent development of leptin resistance. J Neuroendocrinol 1998; 10: 43-49.
26. Williams G, Harrold JA, Cutler DJ. The hypothalamus and the regulation of energy homeostasis: Lifting the lid on a black box. Proc Nutr Soc 2000; 59: 385-396.
27. Eva C, Serra M, Mele P, Panzica G, Oberto A. Physiology and gene regulation of the brain NPY Y1 receptor. Front Neuroendocrinol 2006; 27: 308-339.